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ABSTRACT Therapy that promotes epithelial repair whilst protecting against fibroproliferation is critical
for restoring lung function in acute and chronic respiratory diseases.
Primary human alveolar type II cells were used to model the effects of lipoxin A4 in vitro upon wound
repair, proliferation, apoptosis and transdifferention. Effects of lipoxin A4 upon primary human lung
fibroblast proliferation, collagen production, and myofibroblast differentiation were also assessed.
Lipoxin A4 promoted type II cell wound repair and proliferation, blocked the negative effects of soluble
Fas ligand/tumour necrosis factor α upon cell proliferation, viability and apoptosis, and augmented the
epithelial cell proliferative response to bronchoaveolar lavage fluid (BALF) from acute respiratory distress
syndrome (ARDS). In contrast, Lipoxin A4 reduced fibroblast proliferation, collagen production and
myofibroblast differentiation induced by transforming growth factor β and BALF from ARDS. The effects
of Lipoxin A4 were phosphatidylinositol 3′-kinase dependent and mediated via the lipoxin A4 receptor.
Lipoxin A4 appears to promote alveolar epithelial repair by stimulating epitheial cell wound repair,
proliferation, reducing apoptosis and promoting trans-differentiation of alveolar type II cells into type I
cells. Lipoxin A4 reduces fibroblast proliferation, collagen production and myofibroblast differentiation.
These data suggest that targeting lipoxin actions may be a therapeutic strategy for treating the resolution
phase of ARDS.
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Introduction
Acute inflammatory lung diseases are often associated with epithelial cell loss due to apoptosis and
fibro-proliferative responses. In acute respiratory distress syndrome (ARDS), neutrophilic alveolitis results in
significant alveolar epithelial cell injury and soluble Fas ligand (sFasL) mediated epithelial cell apoptosis [1].
The resolution phase of ARDS is believed to involve repair of the epithelial barrier by transdifferentiation of
type II cells which have stem cell properties into type I epithelial cells [2], as well as alveolar bronchiolisation
of epithelial cells from the distal airway [3]. The degree of alveolar epithelial injury is an important predictor
of outcome [4]. In some cases of ARDS, a marked fibroproliferative response is seen which also negatively
impacts on outcome [5]. Similarly, in chronic lung diseases such as idiopathic pulmonary fibrosis (IPF),
there is lung epithelial cell loss due to apoptosis as well as fibroproliferation with the number of fibroblast
foci relating to mortality [5]. Therefore, a therapy that promoted epithelial repair could be useful in both
acute and chronic respiratory disease but only if it wasn’t also a stimulus for fibro-poliferation.
Lipoxins (LXs) are unique structures derived from arachidonic acid [6]. They were the first mediators
recognised to have dual anti-inflammatory and pro-resolution activities [7], with effects including the
inhibition of neutrophil and eosinophil recruitment and activation [8], inhibition of fibroblast proliferation
[9] and stimulation of macrophage clearance of apoptotic neutrophils in experimental ARDS [10]. LXs
have been described as the endogenous “braking signal” for inflammation [7].
Previous studies have reported that LXA4 is able to attenuate airway inflammation [11]. LXA4 can
promote wound healing and epithelial proliferation in the retinal epithelium [12] and can maintain the
integrity of renal epithelia. Furthermore, LXA4 can regulate airway epithelial tight junction formation [13].
However, what is not known is whether LXA4 has a direct role in modulating adult human lung epithelial
cell and primary human lung fibroblast proliferation and function. In this study, we tested the hypothesis
that LXA4 acts both as a trophic factor for human adult type II alveolar lung epithelial cells, whilst
inhibiting fibro-proliferation and reducing the effects of transforming growth factor β (TGF-β) on primary
human lung fibroblast (HLF) collagen production and myofibroblast differentiation.
Methods
Ethics
Lung tissue was obtained as part of the Midlands Lung Tissue Collaborative. All procedures in this study
were carried out in accordance with approval from the local research ethics committees at the University
of Birmingham (Birmingham, UK). All patients gave written informed consent for the use of their tissue
and clinical data for research purposes.
Primary lung cell culture
Alveolar type II (ATII) cells were extracted from lung distal to the tumour in patients undergoing lung
cancer resection. We used cells from 14 donors for ATII cell extraction who had normal lung function
(eight male, six female, mean age 62.7 years). ATII cells were extracted according to methods described
previously [14]. Average yields of primary human ATII cells were 30.2 million cells per resection with an
average purity of 92% ATII-like cells (see online supplement). Primary HLF from Lonza (Tewkesbury, UK)
were cultured in Dulbecco’s media (ECACC; Sigma, Poole, UK). Experiments were repeated using cells
from at least three separate donors.
Stimuli and inhibitors
ATII cells and fibroblasts were treated with LXA4 (Cayman Chemical Company, Ann Arbor, MI, USA).
Appropriate vehicle controls were used for all experiments with inhibitors. Inhibitors were used at the
following concentrations according to manufacturers’ instructions: LY294002, a PI3-kinase inhibitor
(Calbiochem, Nottingham, UK) at 10 µM; and the LXA4 receptor (ALXR) antagonist, BOC-2
(N-t-Boc-Phe-Leu-Phe-Leu-Phe; GenScript USA Inc., Piscataway, NJ, USA), at 10 µM. Inhibitors were
added to cells 1 h prior to every treatment.
Lessons for clinicians
• By promoting transdifferentiation of alveolar type II cells whilst inhibiting human lung fibroblast
proliferation lipoxin A4 shows potential for a targeted rescue therapy in lung injury.
• The replication of these experiments in epithelial-mesenchymal co-culture models as well as using
lipoxin A4 receptor null mouse models of acute lung injury is essential for confirmation of these results.
• This study has potential implications for developing therapies for preventing and treating the wide
variety of lung diseses where fibroproliferation is a central part of the disease pathophysiology.
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Bronchoalveolar lavage fluid collection
Bronchoalveolar lavage fluid (BALF) from ARDS patients is known to stimulate epithelial repair in the
scratch wound assay in an IL-1 dependent fashion [15]. To test whether LXA4 could augment or synergise
with this effect, we used BALF from patients with ARDS patients mixed 50:50 with appropriate culture
media for each cell type as a positive control stimulus. We used BALF from patients enrolled into the Beta
Agonist Lung Injury Trial-1 (BALTI-1) trial, demographics for whom have been published previously [16].
In vitro alveolar epithelial wound repair assay
Epithelial repair was determined using an in vitro epithelial wound repair assay as described before [17].
To control for the inconsistencies in wound size, only monolayers in which the original wound areas
varied by 10% of the mean were analysed.
Bromodeoxyuridine cell proliferation assay and cell viability assays
Bromodeoxyuridine (BRDU) incorporation was assessed according to manufacturers’ instructions (BRDU
Cell Proliferation Assay; Promega, Southampton, UK). Cell viability after 24 h was assessed adding 20 µL
of Cell Titer 96 aqueous one solution cell proliferation solution (Promega) to cells after culture for 24 h as
described [18].
Flow cytometry
Apoptosis of epithelial cells was assessed as described previously using flow cytometry [19].
Quantitative PCR
Quantitative PCR was performed using commercially obtained primers as outlined in supplementary
methods
HLF proliferation assay in response to ARDS BALF
HLF were plated out at 2500 cells per well. A standard curve of cell counts was pipetted from 1250 to
15000 per well. BALF mixed 50:50 with media was added from 10 ARDS patients. After 24 h BRDU
incorporation was assessed as outlined above. Results were extrapolated from the standard curve. Each
patient sample was run with six replicates upon a single batch of HLF at passage 3.
Statistical analysis
Data were normally distributed and analysed by analysis of variance with Tukey’s test for post hoc
comparisons using Minitab 14.0 (Minitab, State College, PA). A p-value ⩽0.05 was considered significant.
Data are presented as mean±SEM.
Results
LXA4 stimulates ATII cell wound repair and proliferation in vitro
LXA4 increased ATII cell wound closure after 36 h compared with control media. ARDS BALF has previously
been shown to promote epithelial wound repair [15] so we used ARDS BALF to model the stimulus to
epthelial repair responses in ARDS. ARDS BALF increased ATII cell wound closure compared with media
control. The combination of LXA4 and ARDS BALF enhanced the wound repair response (figure 1).
Scratch wound repair can occur due to either spreading of cells and/or proliferation. Cell proliferation
studies confirmed that LXA4 stimulated proliferation of ATII cells in a dose-dependent manner (figure 2).
To determine if PI3-kinase signalling is involved in the lipoxin proliferative response, LY294002 was
incubated with ATII cells at 10 µM for 1 h before LXA4 treatment of ATII cells. LY294002 treatment
reversed the effects of LXA4 (100 nM) on the proliferation of ATII cell compared with control
media–treated cells (figure 3). Pre-treatment of cells with the LXA4 receptor (ALXR) antagonist, BOC-2,
inhibited the effects of LXA4 on the proliferation of ATII cells (figure 3).
LXA4 protects against sFasL and tumour necrosis factor-α actions on ATII cells
sFasL and tumour necrosis factor (TNF)-α inhibited cellular proliferation compared with control
media–treated cells. This effect was attenuated by 100 nM LXA4 pretreatment (figure S1a). The addition of
100 ng·mL−1 sFasL and 100 ng·mL−1 TNF-α to ATII cells, as expected, significantly reduced cellular
viability compared with control cells. Co-treatment with 100 nM LXA4 significantly increased
cellular viability compared with sFasL and TNF combination (p=0.001) (figure S1b); an effect that was
reduced by LXA4 rescue therapy added 30 min after treatment with sFasL (data not shown). sFasL
treatment of ATII cells (which are known to be resistant to apoptosis) increased the number of apoptotic
cells (annexin V+) from 2.61±0.53% in control cells to 9.04±0.94% (p=0.001). Rescue treatment with
LXA4 reduced the number of apoptotic cells to 2.24±0.59% (p=0.001) (figure 4).
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LXA4 promotes aquaporin 5 gene expression whilst reducing surfactant protein C gene
expression by ATII cells
Aquaporin 5 (AQP5) is a membrane protein that mainly facilitates osmotic water transport that has been
used as a type I epithelial cell marker [20, 21]. AQP5 may promote alveolar fluid clearance or maintain
integrity of epithelial barrier [22]. Other roles for AQP5 have been explored in animal lung injury models,
which show that lung injury is associated with a down-regulation of AQP5 expression [23, 24]. To
determine whether LXA4 can promote AQP5 expression, ATII cells were treated by LXA4 for 24 h. LXA4
promoted AQP5 gene expression relative to control group (figure 5a). LXA4-induced AQP5 expression
was blocked by the ALXR antagonist BOC-2 (figure 5a). In contrast LXA4 had no effect on the type I
epithelial marker, receptor for advanced glycation end products (RAGE) (data not shown), but
down-regulated mRNA expression of surfactant protein C (figure 5b), suggesting that LXA4 may promote
transdifferentiation of ATII cells into ATI-like cells.
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FIGURE 2 Effect of lipoxin A4 (LXA4) on alveolar type II cell (ATII) proliferation. LXA4 stimulated the
proliferation of primary human ATII cells. Values of >1-fold of control reflect increased proliferation. Data are
presented as mean±SEM of four independent experiments from four donors.
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FIGURE 1 Effect of lipoxin A4 (LXA4) on alveolar type II cell (ATII) wound repair. LXA4 at different concentrations
was added to monolayers of ATII cells physically wounded with a 1-mL pipette tip. To allow for variability
between cell batches, data are expressed as the mean±SEM percentage of the baseline wound size for each
separate set of experiments for each culture condition of three independent experiments. ARDS: acute
respiratory distress syndrome; BALF: bronchoalveolar lavage fluid.
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FIGURE 3 Pro-proliferative effect of lipoxin A4 (LXA4) is phosphatidylinositol 3′-kinase dependent and
mediated by ALX/formyl peptide L1 receptor. 100 nM LXA4 promoted proliferation of alveolar type II cell (ATII)
cells. Pretreatment with 10 µM LY294002, a phosphatidylinositol 3′-kinase inhibitor, inhibited the effects of
LXA4 on ATII cell proliferation suggesting that the pro-proliferation effects of LXA4 are phosphatidylinositol
3′-kinase dependent. BOC-2, the formyl peptide receptor antagonist, was re-incubated with primary human
ATII cells at 10 µM for 1 h before LXA4 treatment of ATII cells. BOC-2 treatment inhibited the effects of LXA4
on the proliferation of primary human ATII cells suggesting that the promoting proliferation effects of LXA4
are formyl peptide receptor dependent. Data are mean±SEM of three independent experiments.
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FIGURE 4 Effect of lipoxin A4 (LXA4) on soluble Fas ligand induced annexin binding. a) Flow cytometry plots
showing annexin binding. b) Flow cytometry analysis of annexin-positive cells 24 h after treatment with
100 ng·mL−1 soluble Fas ligand (sFasL). LXA4 at 100 nM reduced annexin binding.
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LXA4 inhibits proliferation of primary HLF induced by TGF-β and this effect is PI3-kinase
dependent and blocked by BOC-2
Cell proliferation studies confirmed that 100 nM LXA4 inhibited proliferation of primary HLF induced by
TGF-β. Cells were treated with TGF-β for 24 h with or without preincubation with the PI3 kinase
inhibitor LY294002 (10 µM) or BOC-2 (10 µM). LXA4 inhibited the effects of TGF-β on HLF proliferation
effects that were blocked by both LY294002 and BOC-2 (figure 6).
LXA4 inhibits proliferation of primary HLF induced by BALF from patients with ARDS
ARDS BALF has previously been shown to promote fibroblast proliferation in vitro [25]. To model the in
vivo stimulus for fibroproliferation in ARDS, HLF were treated with a 50:50 mix of BALF from patients
with ARDS. LXA4 inhibited ARDS BALF induced proliferation (figure 7).
LXA4 reduces primary HLF collagen production, N-cadherin, SLUG and α-smooth muscle actin
induced by TGF-β and BALF from patients with ARDS
We investigated by quantitative PCR the mRNA expression of type I collagen, type IV collagen,
N-cadherin, SLUG (snail family transcriptional repressor 2) and α-SMA in HLF induced by TGF-β
10 ng·mL−1. Gene expression of type I collagen, type IV collagen, α-SMA and N-cadherin were increased in
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FIGURE 5 Lipoxin A4 (LXA4) up-regulates aquaporin 5 (AQP5) and downregulates surfactant protein C but has no effect on receptor for advanced
glycation end products. LXA4 promotes AQP5 gene expression while inhibiting surfactant protein C gene expression by primary human alveolar
type II (ATII) cells. To determine whether LXA4 can affect AQP5 and surfactant protein C gene expression, ATII cells were treated by LXA4 for 24 h.
a) AQP5 gene expression: LXA4 only (2.45±0.65 fold) relative to control group, p=0.004. The effect can be blocked by BOC-2 (formyl peptide
receptor antagonist) (LXA4+BOC-2, mean, 0.89±0.12 fold, p=0.007). b) surfactant protein C gene expression: LXA4 only (0.57±0.10 fold) relative to
control group, p=0.001. The effect can be blocked by BOC-2 (formyl peptide receptor antagonist) (LXA4+BOC-2, mean, 1.25±0.19 fold, p=0.01). Data
are mean±SEM of three independent experiments.
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FIGURE 6 Effect of lipoxin A4 (LXA4) on primary human lung fibroblast (HLF) proliferation in response to
transforming growth factor (TGF)-β. Cell proliferation studies confirmed that LXA4 inhibited proliferation of primary
HLF induced by TGF-β. Cultured and serum-deprived cells were treated with 1 ng·mL−1 TGF-β for 24 h with or
without pre-incubation with LY294002 (10 µM) for 1 h, BOC-2 (10 µM) for 1 h. Data are mean±SEM of three
independent experiments. #: p=0.05; +: p=0.05, compared with no treatment group; ¶: p<0.01, compared with TGF-β
only group.
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HLF induced by 24 h of treatment with TGF-β relative to control group. LXA4 significantly inhibited gene
expression of type I collagen, type IV collagen, α-SMA and N-cadherin in HLF induced by TGF-β
compared with TGF-β group respectively (table 1).
We also investigated the effect of ARDS BALF upon type I and IV collagen, α-SMA and SLUG mRNA
expression. Gene expression of type I collagen, type IV collagen, α-SMA and SLUG were increased in HLF
induced by ARDS BALF relative to control group (table 1). LXA4 significantly inhibited gene expression of
type I and IV collagen, α-SMA and SLUG in HLF induced by bronchoalveolar lavage fluid (BALF) from
patients with ARDS (table 1).
Discussion
This study provides evidence for a new mechanism by which LXA4 may contribute to alveolar repair;
namely promoting physical wound closure by inducing proliferation of primary alveolar epithelial cells.
We also demonstrate that LXA4 reduces ATII cells apoptosis induced by sFasL which has been implicated
in the pathogenesis of ARDS. Intriguingly LXA4 also reduced fibroblast proliferation and myofibroblast
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FIGURE 7 Effect of lipoxin A4 (LXA4) on primary human lung fibroblast (HLF) proliferation in response to acute
respiratory distress syndrome (ARDS) bronchoalveolar lavage fluid (BALF). BALF from patients with ARDS
stimulated proliferation of primary HLF. LXA4 inhibited the proliferation of primary HLF induced by BALF from
patients with ARDS. Data are mean±SEM of three independent experiments.
TABLE 1 Summary of the different types of gene expression in response to treatment of
different stimulations
Gene type TGF-β LXA4 + TGF-β BALF LXA4 + BALF
Type I collagen 323.35±168.07* 14.87±7.53# 9.47±3.78* 5.69±2.77+
Type IV collagen 27.04±14.46* 5.81±2.55# 13.48±3.67* 1.94±0.98++
N-cadherin 7.93±0.3** 1.95±0.37## 8.51±2.73* 0.67±0.31++
α-SMA 22.36±2.93** 7.24±0.62## 4.01±1.05* 1.34±0.62++
Data are presented as mean±SEM fold change in gene expression over control. Lipoxin A4 (LXA4) reduces
primary human lung fibroblast (HLF) collagen production, N-cadherin, SLUG and α-smooth muscle actin
(α-SMA) induced by transforming growth factor β (TGF-β) and bronchoalveolar lavage fluid (BALF) from
patients with acute respiratory distress syndrome (ARDS). Gene expression of type I collagen, type IV
collagen, α-SMA and N-cadherin were increased in HLF induced by TGF-β relative to control group. LXA4
significantly inhibited gene expression of type I collagen, type IV collagen, N-cadherin and α-SMA in HLF
induced by TGF-β compared to TGF-β group. Gene expression of type I collagen, type IV collagen, SLUG
and α-SMA and were increased in HLF induced by ARDS bronchoalveolar lavage fluid (BALF) relative to
control group. LXA4 significantly inhibited gene expression of type I collagen, type IV collagen, α-SMA and
SLUG in HLF induced by BALF from patients with ARDS (compared to BALF group). Data are mean±SEM of
three independent experiments. *: p<0.05; and **: p<0.01 relative to control group, respectively; #: p<0.05,
##: p<0.01 compared with TGF-β group, respectively; +: p<0.05; and ++: p<0.01 compared with the
bronchoalveolar lavage fluid (BALF) group, respectively.
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differentiation in response to TGF-β and ARDS BALF (as suggested by inhibiting collagen production and
α-SMA expression) suggesting beneficial effects upon aberrant fibroproliferative responses.
Epithelial damage is a hallmark of ARDS [26] and LXA4 has been implicated in both anti-inflammatory
actions on epithelial cells as well as promoting wound healing. LXA4 directly regulated several functional
responses by the injured human bronchial epithelial cells, including inhibition of acid-induced IL-6 and
promoting restitution of injured airway epithelium. In the cornea, LXA4 also stimulated corneal epithelial
wound healing following eye injury [12, 27]. LXA4 has also been shown recently to stimulate alveolar fluid
clearance by an effect upon epithelial sodium channel and sodium–potassium ATPases in experimental
lung injury [28]. The role of lipoxin in apoptosis has been a matter of debate [29]. For instance, a
pro-apoptotic effect upon renal interstitial fibroblasts after treatment with LXA4 has been described [30],
whereas it promotes survival of retinal pigment epithelial cells as well as corneal epithelial cells [12, 31].
We therefore investigated the effects of LXA4 on physical wound repair, cellular proliferation, and
apoptosis in ATII cells which are responsible for repair after lung injury.
LXA4 increased ATII cell wound repair and proliferation and our study also shows that the mitogenic
response of ATII cells to LXA4 is mediated via activation of ALX/formyl peptide receptor (FPR)-2
receptor. Furthermore, LXA4 inhibited apoptosis and reduced cell death in sFasL/TNF-α treated cells even
when given after the onset of injury and, therefore, has potential as a rescue therapy.
The repair of the alveolar epithelium following injury is believed to involve the transdifferentiation of ATII
cells into type I cells. LXA4 increased expression of AQP5 (type I marker) but not RAGE in ATII via
activation of ALX/FPLR-1 supporting a potential role for LXA4 in promoting fluid transport. LXA4
treatment reduced expression of surfactant protein C (type II markers) in vitro suggesting that it may
promote transdifferentiation of ATII cells towards the ATI phenotype. The role of Lipoxin in cell
proliferation, migration and would repair has also been documented in normal and cystic fibrosis airway
epithelial cell lines [32]. Moreover, LXA4 has also been reported to slow mouse fibroblast migration and
scratch wound closure [2].
Recent data have demonstrated an aspirin-triggered LXA4-reduced inflammation and fibrosis in murine
bleomycin-induced pulmonary fibrosis [33]. Further up-regulation of the LXA4 receptor in vivo is
associated with reduced collagen accumulation in the bleomycin-induced model of lung fibrosis [34].
Recent data also suggest human mesenchymal stem cells promote the resolution of acute lung injury in
part through LXA4 signalling via formyl peptide receptor 2 (ALX/FPR) [35]. We demonstrated that LXA4
inhibited TGF-β induced proliferation in primary HLF via activation of ALX/FPLR-1 and was mediated
via activation of the PI3/Akt signalling pathway. This result is in agreement with previously reported
evidence that LXA4 inhibited the proliferation of HLF cell line evoked by connective tissue growth factor
(CTGF) [9].
It is established that, as fibroblasts differentiate to myofibroblasts in response to TGF-β, there is
up-regulation of levels of α-SMA and a markedly enhanced ability to secrete extracellular matrix proteins
[36, 37]. Our data show LXA4 significantly inhibits gene expression of type I collagen, type IV collagen
and α-SMA in HLF induced by TGF-β. We also demonstrate for the first time that ARDS BALF
stimulated the expression of markers of myofibroblast differentiation when incubated with normal HLF; an
effect that was blocked by LXA4. Our data therefore suggest that LXA4 has differential effects upon ATII
and HLF cells in vitro; both promoting epithelial repair whilst reducing fibroproliferation. This differential
effect is potentially vitally important for LXA4 and its more stable analogues to be use as novel therapies
in both acute and chronic inflammatory lung diseases.
Limitations
This study has limitations: we have been unable to assess levels of LXA4 in patient samples due to the lack
of reliable ELISA assays for the analysis. There is little information about LXA4 in patient samples with
sepsis and ARDS and this is something that should be addressed. However, recently LXA4 levels have been
reported to be lower in patients with sepsis [38]. Similarly, we lack tissue from patients with ARDS to test
whether ALX receptor expression is altered in ARDS.
Further, our assessments of ATII/ATI and fibroblast/myofibroblast phenotypes are dependent upon
quantitative PCR rather than protein expression but are consistent with reported effects in other tissues.
Quantification of additional cell type markers at the protein level correlating with morphological features
in the in vitro cultured cells would be useful to support transdifferentiation of ATII cells. However, the
study of ATII cell biology is restricted by lack of specific markers. Surfactant protein expression has been
widely used as a definitive marker to identify type II cells; likewise, aquaporin 5 as marker for type I cells.
Unfortunately, we are unable to retrospectively analyse further markers owing to lack of frozen cells from
the same batches as used in the marker analysis in this study.
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Flow cytometry analysis for CD208, a member of the lysosomal-associated membrane protein family and a
marker of normal ATII cells, would supplement the pro-transdifferentiation role of lipoxin at the protein
level. Also given the importance of the effect of co-culture of epithelial cells with mesechymal cells in
ligand responsiveness [39] it will be important to address these issues in human three-dimensional
co-culture models. Furthermore, future experiments will have to substantiate results of this study using
wild type and FPR null mouse model of ALI. In addition, as LXA4 has a shorter half-life in vivo,
experiments using stable analogues that have greater efficacy is vital to establish its functional role. There
is recent evidence that a stable epi-LXA4 analogue reduced bleomycin-induced pulmonary fibrosis in mice
[33] supporting a role for LXA4 as a potential treatment for lung injury/fibrosis. Additionally, a recent
study has reported that resolvin D2 which is more stable than LXA4, and activates similar receptors
demonstrating similar effects on fibroblast migration and proliferation [40].
In conclusion, the results from our study demonstrate that LXA4 increased wound repair and proliferation
of primary human ATII cells in vitro. LXA4 protected ATII cells from pro-apoptotic stimuli even when
given after the initial injury. LXA4 promoted the expression of the type I marker, AQP5, with reduction in
surfactant protein C by ATII like cells potentially promoting transdifferentiation- an important part of
repair after alveolar injury. Since the restoration of a confluent alveolar epithelial cell barrier is a critical
aspect of alveolar repair, for which there is no targeted rescue therapy currently available [8], we believe
that LXA4 has therapeutic potential for the ARDS which is associated with significant alveolar epithelial
damage.
We have also demonstrated that LXA4inhibited HLF proliferation, HLF collagen production and α-SMA
expression in response to both TGF-β and ARDS BALF. As it stands, the function of LXA4 is not fully
charecterised in alveolar epithelial cells and in lung fibrosis. Besides, these results are novel and interesting
for the reason that primary human lung cells often respond very differently to animal models.
These data have important implications for future efforts in developing an efficient therapeutic strategy for
preventing and treating the fibroproliferative phase of ARDS as well as chronic diseases such as IPF by
targeting LXA4 actions. Further experiments are necessary to understand the basic mechanism underlying
the anti-fibrotic effects of LXA4, which are currently under investigation.
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